Completed PHASE3 INTERVENTIONAL 2-arm NCT00798317

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.

Sponsor: ThromboGenics

Conditions Vitreomacular Adhesion

Interventions Ocriplasmin 125µg Placebo

Updated 7 times since 2017 Last updated: Dec 2, 2014 Started: Dec 31, 2008 Primary completion: Jun 30, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00798317, this PHASE3 trial focuses on Vitreomacular Adhesion and remains completed. Sponsored by ThromboGenics, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ThromboGenics

Data source: ThromboGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Alicante, Spain , Arlington, United States , Austin, United States , Barcelona, Spain , Bonn, Germany , Boston, United States , Bremen, Germany , Brno, Czechia , Campbell, United States and 37 more locations